TWI330528B - - Google Patents
Download PDFInfo
- Publication number
- TWI330528B TWI330528B TW096100680A TW96100680A TWI330528B TW I330528 B TWI330528 B TW I330528B TW 096100680 A TW096100680 A TW 096100680A TW 96100680 A TW96100680 A TW 96100680A TW I330528 B TWI330528 B TW I330528B
- Authority
- TW
- Taiwan
- Prior art keywords
- cells
- compound
- test
- cell line
- growth
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 claims description 74
- 210000004881 tumor cell Anatomy 0.000 claims description 39
- 150000001875 compounds Chemical class 0.000 claims description 29
- 206010006187 Breast cancer Diseases 0.000 claims description 21
- 208000026310 Breast neoplasm Diseases 0.000 claims description 21
- 206010060862 Prostate cancer Diseases 0.000 claims description 20
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 20
- 230000012010 growth Effects 0.000 claims description 13
- 201000007270 liver cancer Diseases 0.000 claims description 13
- 208000014018 liver neoplasm Diseases 0.000 claims description 13
- 230000003078 antioxidant effect Effects 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- -1 gamma Chemical compound 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 53
- 239000000284 extract Substances 0.000 description 26
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 23
- 229930012538 Paclitaxel Natural products 0.000 description 21
- 229960001592 paclitaxel Drugs 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 241001486992 Taiwanofungus camphoratus Species 0.000 description 20
- 238000000338 in vitro Methods 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 235000008078 Arctium minus Nutrition 0.000 description 8
- 238000003018 immunoassay Methods 0.000 description 8
- 241000208843 Arctium Species 0.000 description 7
- 235000003130 Arctium lappa Nutrition 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 150000003648 triterpenes Chemical class 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- FWFSEYBSWVRWGL-UHFFFAOYSA-N cyclohex-2-enone Chemical compound O=C1CCCC=C1 FWFSEYBSWVRWGL-UHFFFAOYSA-N 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 239000012139 lysis buffer Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- YBSIPTHESHMQDU-UHFFFAOYSA-N C(CCCCCCCCC)C(=CC)CCC=C(CCC=C(C)CCCCCCCCCC)CCCCCCCCCC Chemical compound C(CCCCCCCCC)C(=CC)CCC=C(CCC=C(C)CCCCCCCCCC)CCCCCCCCCC YBSIPTHESHMQDU-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 229940041181 antineoplastic drug Drugs 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 241000123370 Antrodia Species 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000009098 adjuvant therapy Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cis-cyclohexene Natural products C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000007877 drug screening Methods 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000000469 ethanolic extract Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 3
- 229960004844 lovastatin Drugs 0.000 description 3
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000010304 tumor cell viability Effects 0.000 description 3
- 239000002023 wood Substances 0.000 description 3
- DVORYMAGXQGBQK-UHFFFAOYSA-N zhankuic acid A Natural products CC12CCC(=O)C(C)C1CC(=O)C1=C2C(=O)CC2(C)C(C(CCC(=C)C(C)C(O)=O)C)CCC21 DVORYMAGXQGBQK-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- RJXJHEYXZURDJH-UHFFFAOYSA-N 4,7-dimethoxy-5-methyl-1,3-benzodioxole Chemical compound COC1=CC(C)=C(OC)C2=C1OCO2 RJXJHEYXZURDJH-UHFFFAOYSA-N 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- ONFPYGOMAADWAT-OXUZYLMNSA-N Dehydroeburicoic acid Chemical compound CC1(C)[C@@H](O)CC[C@]2(C)C3=CC[C@]4(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(O)=O)CC[C@@]4(C)C3=CC[C@H]21 ONFPYGOMAADWAT-OXUZYLMNSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 230000017066 negative regulation of growth Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229930009674 sesquiterpene lactone Natural products 0.000 description 2
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000004565 tumor cell growth Effects 0.000 description 2
- 229930188837 zhankuic acid Natural products 0.000 description 2
- NDNKBYRXHKLSJQ-UXYVAYPWSA-N (2r)-2-[(3s,5r,10s,13r,14r,15s,17r)-15-acetyloxy-3-hydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,12,15,16,17-octahydro-1h-cyclopenta[a]phenanthren-17-yl]-6-methyl-5-methylideneheptanoic acid Chemical compound CC1(C)[C@@H](O)CC[C@]2(C)C3=CC[C@]4(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(O)=O)C[C@H](OC(C)=O)[C@@]4(C)C3=CC[C@H]21 NDNKBYRXHKLSJQ-UXYVAYPWSA-N 0.000 description 1
- DVORYMAGXQGBQK-HPRYJKPLSA-N (2s,6r)-2-methyl-3-methylidene-6-[(4s,5s,10s,13r,14r,17r)-4,10,13-trimethyl-3,7,11-trioxo-1,2,4,5,6,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]heptanoic acid Chemical compound C([C@@]12C)CC(=O)[C@@H](C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CCC(=C)[C@H](C)C(O)=O)C)CC[C@H]21 DVORYMAGXQGBQK-HPRYJKPLSA-N 0.000 description 1
- TWISSXUWVGIUBP-UHFFFAOYSA-N (4alpha,7beta)-7-Hyddroxy-4-methyl-3,11-dioxoergosta-8,24(28)-dien-26-oic acid Natural products CC12CCC(=O)C(C)C1CC(O)C1=C2C(=O)CC2(C)C(C(CCC(=C)C(C)C(O)=O)C)CCC21 TWISSXUWVGIUBP-UHFFFAOYSA-N 0.000 description 1
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- PMHCHLYGCHPBEC-CYFVRWTGSA-N (6R)-2-methyl-3-methylidene-6-[(4S,10S,13R,17R)-4,10,13-trimethyl-3,11-dioxo-2,4,5,6,7,12,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]heptanoic acid Chemical compound O=C1[C@H](C2CCC=3C4=CC[C@H]([C@@H](CCC(C(C(=O)O)C)=C)C)[C@]4(CC(C=3[C@]2(CC1)C)=O)C)C PMHCHLYGCHPBEC-CYFVRWTGSA-N 0.000 description 1
- ZPSJWLSADLCKBZ-GIMPTUAXSA-N (6r)-6-[(4s,7s,10s,13r,17r)-7-hydroxy-4,10,13-trimethyl-3,11-dioxo-2,4,5,6,7,12,16,17-octahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methyl-3-methylideneheptanoic acid Chemical compound C([C@@]12C)CC(=O)[C@@H](C)C1C[C@H](O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CCC(=C)C(C)C(O)=O)C)CC=C21 ZPSJWLSADLCKBZ-GIMPTUAXSA-N 0.000 description 1
- NIIPNAJXERMYOG-UHFFFAOYSA-N 1,1,2-trimethylhydrazine Chemical compound CNN(C)C NIIPNAJXERMYOG-UHFFFAOYSA-N 0.000 description 1
- ZTEHOZMYMCEYRM-UHFFFAOYSA-N 1-chlorodecane Chemical compound CCCCCCCCCCCl ZTEHOZMYMCEYRM-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- NDNKBYRXHKLSJQ-UHFFFAOYSA-N 15alpha-acetyldehydrosulphurenic acid Natural products CC(C)C(=C)CCC(C1CC(OC(=O)C)C2(C)C3=CCC4C(C)(C)C(O)CCC4(C)C3=CCC12C)C(=O)O NDNKBYRXHKLSJQ-UHFFFAOYSA-N 0.000 description 1
- JXBSHSBNOVLGHF-UHFFFAOYSA-N 2,6,10-trimethyldodeca-2,6,10-triene Chemical compound CC=C(C)CCC=C(C)CCC=C(C)C JXBSHSBNOVLGHF-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- WTSUWKBKPMVEBO-UHFFFAOYSA-N 4alpha-4-Methyl-3,11-dioxoergosta-8,24(28)-dien-26-oic acid Natural products CC12CCC(=O)C(C)C1CCC1=C2C(=O)CC2(C)C(C(CCC(=C)C(C)C(O)=O)C)CCC21 WTSUWKBKPMVEBO-UHFFFAOYSA-N 0.000 description 1
- WAAWMJYYKITCGF-WTPIMUJOSA-N 5alpha-ergostane Chemical compound C([C@@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C)C(C)C)[C@@]2(C)CC1 WAAWMJYYKITCGF-WTPIMUJOSA-N 0.000 description 1
- 241000173529 Aconitum napellus Species 0.000 description 1
- PMHCHLYGCHPBEC-UHFFFAOYSA-N Antcin E Natural products CC(CCC(=C)C(C)C(=O)O)C1CC=C2C3=C(C(=O)CC12C)C4(C)CCC(=O)C(C)C4CC3 PMHCHLYGCHPBEC-UHFFFAOYSA-N 0.000 description 1
- ZPSJWLSADLCKBZ-UHFFFAOYSA-N Antcin F Natural products CC12CCC(=O)C(C)C1CC(O)C1=C2C(=O)CC2(C)C(C(CCC(=C)C(C)C(O)=O)C)CC=C21 ZPSJWLSADLCKBZ-UHFFFAOYSA-N 0.000 description 1
- 244000294263 Arctium minus Species 0.000 description 1
- 241000045403 Astragalus propinquus Species 0.000 description 1
- 235000017386 Brosimum utile Nutrition 0.000 description 1
- 241000985962 Brosimum utile Species 0.000 description 1
- PONMMBJIVKHXIF-UHFFFAOYSA-N C1(C=CCCC1)=O.CC(=CC)CCC=C(CCC=C(C)C)C Chemical compound C1(C=CCCC1)=O.CC(=CC)CCC=C(CCC=C(C)C)C PONMMBJIVKHXIF-UHFFFAOYSA-N 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- 241000386860 Cinnamomum micranthum Species 0.000 description 1
- ONFPYGOMAADWAT-UHFFFAOYSA-N Dehydroeburicolic acid Natural products CC1(C)C(O)CCC2(C)C3=CCC4(C)C(C(CCC(=C)C(C)C)C(O)=O)CCC4(C)C3=CCC21 ONFPYGOMAADWAT-UHFFFAOYSA-N 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- ZWMDJBNGXKAIRO-UHFFFAOYSA-N Methyl antcinate H Natural products CC12CCC(O)C(C)C1CC(=O)C1=C2C(=O)C(O)C2(C)C(C(C)CCC(=C)C(C)C(=O)OC)CCC21 ZWMDJBNGXKAIRO-UHFFFAOYSA-N 0.000 description 1
- 102100025311 Monocarboxylate transporter 7 Human genes 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 108091006603 SLC16A6 Proteins 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 235000005811 Viola adunca Nutrition 0.000 description 1
- 240000009038 Viola odorata Species 0.000 description 1
- 235000013487 Viola odorata Nutrition 0.000 description 1
- 235000002254 Viola papilionacea Nutrition 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TXEJUZMIQVTZHO-UHFFFAOYSA-N Zhankuic acid B Natural products CC12CCC(O)C(C)C1CC(=O)C1=C2C(=O)CC2(C)C(C(CCC(=C)C(C)C(O)=O)C)CCC21 TXEJUZMIQVTZHO-UHFFFAOYSA-N 0.000 description 1
- LVFHKUZOQUATIE-UHFFFAOYSA-N Zhankuic acid C Natural products CC12CCC(O)C(C)C1CC(=O)C1=C2C(=O)C(O)C2(C)C(C(CCC(=C)C(C)C(O)=O)C)CCC21 LVFHKUZOQUATIE-UHFFFAOYSA-N 0.000 description 1
- 229940023019 aconite Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- WTSUWKBKPMVEBO-QNMMDLTMSA-N antcin A Chemical compound C([C@@]12C)CC(=O)[C@@H](C)[C@@H]1CCC1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CCC(=C)[C@H](C)C(O)=O)C)CC[C@H]21 WTSUWKBKPMVEBO-QNMMDLTMSA-N 0.000 description 1
- TWISSXUWVGIUBP-IRXLFGEOSA-N antcin C Chemical compound C([C@@]12C)CC(=O)[C@@H](C)[C@@H]1C[C@H](O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CCC(=C)[C@H](C)C(O)=O)C)CC[C@H]21 TWISSXUWVGIUBP-IRXLFGEOSA-N 0.000 description 1
- ZPSJWLSADLCKBZ-BJLSYBTBSA-N antcin F Natural products C[C@H](CCC(=C)[C@H](C)C(=O)O)[C@H]1CC=C2C3=C(C(=O)C[C@]12C)[C@@]4(C)CCC(=O)[C@@H](C)[C@@H]4C[C@@H]3O ZPSJWLSADLCKBZ-BJLSYBTBSA-N 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001644 anti-hepatocarcinoma Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical class C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- OQUUTERJWTYTHP-UHFFFAOYSA-N butanedioate;1h-tetrazol-1-ium Chemical compound [NH2+]1C=NN=N1.[NH2+]1C=NN=N1.[O-]C(=O)CCC([O-])=O OQUUTERJWTYTHP-UHFFFAOYSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- DVXFDXIVWQWLIU-UHFFFAOYSA-N dehydroeburiconic acid Natural products CC1(C)C(=O)CCC2(C)C3=CCC4(C)C(C(CCC(=C)C(C)C)C(O)=O)CCC4(C)C3=CCC21 DVXFDXIVWQWLIU-UHFFFAOYSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000009004 jinqing Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- ZQIOPEXWVBIZAV-ZKYCIREVSA-N lanostane Chemical compound CC([C@@H]1CC2)(C)CCC[C@]1(C)[C@@H]1[C@@H]2[C@]2(C)CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 ZQIOPEXWVBIZAV-ZKYCIREVSA-N 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- ZWMDJBNGXKAIRO-PRBDMEKXSA-N methyl antcinate H Chemical compound C([C@@]12C)C[C@@H](O)[C@@H](C)[C@@H]1CC(=O)C1=C2C(=O)[C@H](O)[C@]2(C)[C@@H]([C@H](C)CCC(=C)C(C)C(=O)OC)CC[C@H]21 ZWMDJBNGXKAIRO-PRBDMEKXSA-N 0.000 description 1
- 229930183875 methylantcinate Natural products 0.000 description 1
- AJDUTMFFZHIJEM-UHFFFAOYSA-N n-(9,10-dioxoanthracen-1-yl)-4-[4-[[4-[4-[(9,10-dioxoanthracen-1-yl)carbamoyl]phenyl]phenyl]diazenyl]phenyl]benzamide Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2NC(=O)C(C=C1)=CC=C1C(C=C1)=CC=C1N=NC(C=C1)=CC=C1C(C=C1)=CC=C1C(=O)NC1=CC=CC2=C1C(=O)C1=CC=CC=C1C2=O AJDUTMFFZHIJEM-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 150000003429 steroid acids Chemical class 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000025444 tumor of salivary gland Diseases 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000001043 yellow dye Substances 0.000 description 1
- DVORYMAGXQGBQK-QCMFUGJUSA-N zhankuic acid A Chemical compound C([C@@]12C)CC(=O)[C@@H](C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CCC(=C)C(C)C(O)=O)C)CC[C@H]21 DVORYMAGXQGBQK-QCMFUGJUSA-N 0.000 description 1
- TXEJUZMIQVTZHO-JNXQNPAGSA-N zhankuic acid B Chemical compound C([C@@]12C)C[C@@H](O)[C@@H](C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CCC(=C)C(C)C(O)=O)C)CC[C@H]21 TXEJUZMIQVTZHO-JNXQNPAGSA-N 0.000 description 1
- LVFHKUZOQUATIE-NIQDNRFFSA-N zhankuic acid C Chemical compound C([C@@]12C)C[C@@H](O)[C@@H](C)[C@@H]1CC(=O)C1=C2C(=O)[C@H](O)[C@]2(C)[C@@H]([C@@H](CCC(=C)C(C)C(O)=O)C)CC[C@H]21 LVFHKUZOQUATIE-NIQDNRFFSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/02—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains containing only carbon and hydrogen atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Fats And Perfumes (AREA)
Description
1330528 九、發明說明: 【發明所屬之技術領域】 本發明係關於一種新穎化合物’尤其係關於一種由牛 樟芝(J)萃取物中所分離純化之化合 物及其於抑制腫瘤細胞生長之應用。 【先前技術】 牛樟芝,又稱樟芝、牛棒兹、 紅樟、紅樟芝、樟藏或樟窟内蔬等,為臺灣特有種真菌, 只生長於臺灣山區海拔450〜2000公尺間之牛棒樹 (Hay )的中空腐朽心材内壁上,因 此是由樹幹内面生長出子實體。牛樟樹目前主要分佈於桃 園、南投等山區,由於牛樟樹是台灣數量極為稀少的保育 類樹種’加上人為的盜伐,使得寄生於其中方能生長之野 生牛樟芝數量更形稀少,且由於其生長相當緩慢,生長期 亦僅在六月至十月之間,因此價格非常昂貴。 / 牛樟芝之子實體為多年生,無柄,呈木栓質至木質, 其外形多變’有板狀、鐘狀、馬蹄狀或塔狀。初時為扁平 型,貼生於木材表面,之後其前緣會略為捲曲魅起,而呈 板塊狀(層紋板狀)或如鐘乳石狀。牛樟芝頂部表面呈褐 色至黑褐色,具不明顯的皺紋,有光澤,邊緣平而純,其 腹面則為橘紅色或局部黃色,並有許多細孔。 “ 5 1330528 此牛樟芝具有強烈的黃樟香氣,其曝乾後槐色成 白色#味極古’民間將其用作解毒、保肝、抗癌之草 藥牛樟义如@般食藥用的簟益類,具有許多複雜的成 分,已知的生理活性成分中,包括:多酿體 (pdysacchaddes,如:萄聚畴)、三莊類化合物 (trit—ds)、超氧歧化酶(寧r〇xide此刪挪,s〇d)、 腺苷(adenosine)、蛋白質(含免疫球蛋白)、維生素(如維 生素B、於驗酸)、微量元素(如:舞、碟及錯等)、核 酸、凝集素、絲酸、固_、木f素以及血壓穩定物質 (如:antodia acid)等,這些生理活性成分被認為具有抗 腫瘤、增加免疫能力、抗過敏、抑制血小板凝集、抗病毒、 抗細菌、抗高血壓、降血糖、降膽固醇以及保護肝臟等功 能。 牛樟芝眾多成分中以三萜類化合物被研究的最多, 三萜類化合物是由三十個碳元素結合成六角形或五角形 天然化合物之總稱’牛樟芝所具之苦味即主要來自三萜類 此成分。1995年時,Cherng等人發現牛樟芝子實體萃取 物中含有三種新的以麥角甾烷(ergostane)為骨架的三萜 類化合物:antcin A、antcin B 與 antcin C( Cherng, I. H.,and Chiang, H. C. 1995. Three new triterpenoids from Antrodia J. Nat. Prod. 58:365-371 )。Chen 等人以乙醇 萃取樟芝子實體後發現zhankuic acid A、zhankuic acid B 及zhankuic acid C等三種三萜類化合物(Chen, C. H.,and Yang, S. W. 1995. New steroid acids from Antrodia 6 1330528 cinnamomea, - a fungus parasitic on Cinnamomum micranthum. J. Nat. Prod. 58:1655-1661)。此外,Chiang 等人於1995年也由子實體萃取物中發現另外三種分別 為倍半萜内酯(sesquiterpene lactone)與兩種雙酚類衍生 物的新三萜類化合物,此即antrocin,4,7-二甲氧基-5-甲 基-1,3-苯並二氧環(p-dimethoxy-S-methy-lJ-benzodioxole) 與 2,2·,5,5'-四 甲氧基-3,4,3',4,-雙-亞 曱二氧 基 _6,6’-二甲基聯苯(2,2’,5,5'七^11161;11(^-3,4,3’,4|-1^-methylenedioxy-6,6'- dimethylbiphenyl) (Chiang, H. C., Wu, D. P., Cherng, I. W., and Ueng, C. H. 1995. A sesquiterpene lactone, phenyl and biphenyl compounds from Antrodia cinnamomea. Phytochemistry. 39:613-616)。到了 1996 年, Cherng等人以同樣分析方法再度發現四種新的三莊類化 合物:antcin E、antcin F、methyl antcinate G、methyl antcinate H ( Cherng,I· H.,Wu,D. P.,and Chiang, H. C. 1996. Triteroenoids from Antrodia cinnamomea. Phytochemistry. 41:263-267);而 Yang 等人則發現 了二種 以麥角甾烧為骨架的新化合物zhankuic acid D、zhankuic acid E,和三種以羊毛留烧(lanostane)為骨架的新化合 物:15 α -乙醯-去氫硫色多孔菌酸(15 α -acetyl-dehydrosulphurenic acid )、去氫齒孔酸 (dehydroeburicoic acid )與去水硫色多孔菌酸 (dehydrasulphurenic acid) ( Yang, S. W., Shen, Y. C., and Chen, C. H. 1996. Steroids and triterpenoids of Antrodia 7 1330528
式(2)之化合物,其化學名為4-羥基-2,3-二曱氧基_6· 甲基-5 (3,7,11-三曱基-2,6,10-十二碳三烯)-2-環己歸酿j (4-hydr〇xy_2,3-dimethoxy-6-methy-5(3,7,l 1-trimethyl-d〇 deca-2,6,10-trienyl)-cyclohex-2-enone ),分子式為 e24H38()4 ’外觀為淡黃色粉末狀,分子量為390。 本發明中式(1)、式(2)之化合物係分離純化自牛掉芝 水萃取物或有機溶劑萃取物,有機溶劑可包括醇類(例如 曱醇、乙醇或丙醇)、酯類(例如乙酸乙酯)、烷類(例 如己燒)或鹵烷(例如氯曱烷、氯乙烷),但並不以此為 限,其中較佳者為醇類,更佳者為乙醇。
藉由前述化合物,本發明係將其應用於抑制腫瘤細 胞生長上’使能進-步應用於治療癌症之醫藥組成份中, 增益癌症之治療絲。本發魏合物得應用之翻包括對 =乳癌腫瘤細胞、肝癌_細胞與攝護腺癌腫瘤細胞等細 之生長產生抑制效果’使該等腫瘤細胞無法迅速生長, :抑制腫瘤之增生’延緩腫瘤之惡化,因此,可進一步 1於礼癌、肝癌與攝護腺癌等癌症之治療。 利用癌本式⑴或/與式(2)之化合物 ㈣與攝_癌等醫藥㈣物之成分 9 1330528 中,藉以抑制該等腫瘤細胞的生長。前述醫藥組成物除包 括有效劑4之式⑴或/與式⑺之化合物外,尚可包括藥學 上可接受的載體。載體可為賦形劑(如水)、填充劑(如 蔗糖或澱粉)、黏合劑(如纖維素衍生物)、稀釋劑、崩 解劑、吸收促進劑或甜味劑,但並未僅限於此。本發明醫 藥組成物可依一般習知藥學之製備方法生產製造,將式(1) 或/與式(2)有效成分劑量與一種以上之載體相混合,製備 出所需之劑型,此劑型可包括錠劑、粉劑、粒劑、膠囊或 其他液體製劑,但未以此為限。 此外,由於本發明中之化合物同時具有抗氧化活 性,因此亦可將之添加於保健食品、飲食品、醫藥品、化 妝品當中,藉由其抗氧化能力達到預防心血管疾病或避免細 胞突變等效用,使助益於施用人體之健康。 以下將配合圖式進一步說明本發明的實施方式,下述 所列舉的實施例係用以闡明本發明,並非用以限定本發明 之範圍,任何熟習此技藝者,在不脫離本發明之精神和範 圍内,當可做些許更動與潤飾,因此本發明之保護範圍當 視後附之申請專利範圍所界定者為準。 田 【實施方式】 首先取牛樟芝(乂《iroi/z.a 如)菌絲體、子實 體或一者之混合物,利用習知萃取方式,以水或有機容劑 1330528 進行萃取,_取得牛料料取物或有· 其中,有機溶劑可包括醇類(例如甲醇、乙醇或丙 醋類(例如乙酸⑽)、燒類(例如己燒)或錢(例如 乳甲烧1乙燒),但並不以此為限。其中較佳者為醇類, 更佳者為乙醇。
經萃取過奴牛樟芝水萃取物或有機賴萃取物, 可進-步藉由高效液相層析加以分離純化,之後再對每一 分液(fraction)進行抑癌效果的測試。最後,則針對具 抑癌效果之錄進行成分分析,將可能產生抑癌效果的成 分再分別進-步做不目癌症軸細就_效果測試。最 終即發現本發财如式⑴/式(2)之化合物係具有抑制不 同癌症腫瘤細胞生長之效果,且該化合物經與習知文 對’並未曾發現於牛樟芝中,因此係—卿、之化合物。
為方便說明本發明,以下將以式(2)之4_經基·2,3-二甲 氧基_6-甲基-5 (3,7,11-三甲基_2,6,1〇_十二碳三稀)_2_環 己烯_化合物進行說明。此外,為證實4麟·2,3·二甲 氧基-6-甲基-5 (3,7,11-三曱基_2,6,1〇-十二碳三稀)_2環 己烯酮化合物對腫瘤細胞生之抑制效果,本發明中係以 ΜΤΤ刀析法根據美國國家癌症研究所(Nati〇nai cancer Institute, NCI)抗腫瘤藥物筛檢模式,對包括乳癌、肝癌 與攝濩腺癌等腫瘤細胞進行細胞存活率之測試。由該些測 試證實,4_經基·2,3_二甲氧基·6_甲基_5 (3,7,n_三曱基 -2,6,l〇-十二碳三烯)·2_環己烯酮對於乳癌腫瘤細胞(包 11 1330528 括MCF-7與]νΐΓ)Α-ΜΒ·231 )、肝癌腫瘤細胞(包括Hep 3B與Hep G2)與攝護腺癌腫瘤細胞(包括LNCaP與 DU-145)等皆可降低其存活率,相對之下並可同時降低 生長半抑制率所需濃度(即IC50值),因此得藉由4-羥 基-2,3-二甲氧基_6_甲基_5(3,7,11_三曱基-2,6,10-十二碳 三稀)-2-環己稀酮,應用於包括乳癌、肝癌與攝護腺癌 等腫瘤細胞之生長抑制上,而進一步可利用於乳癌、肝癌 與攝護腺癌等癌症之治療。茲對前述實施方式詳盡說明如 下: 實施例1 : 4-經基_2,3-二曱氧基-6-曱基-5( 3,7,11_三甲基-2,6,l〇-十二 碳三浠)-2·環己烯鲷的分離 將100克左右之牛樟芝菌絲體、子實體或二者之混 合物,置入二角錐形瓶中,加入適當比例的水與醇類 (70%〜100%醇類水溶液),於20〜25°C下攪拌萃取至少 1小時以上’之後以濾紙及0.45 μιη濾膜過濾,收集萃取 液0 將前述收集之牛樟芝萃取液,利用高效能液相層析 儀(High Performance Liquid chromatography),以 rpi8 的 層析管(column)進行分析,並以曱醇(A)及〇.ι〇/0〜〇 5%醋 酸水溶液(B)做為移動相(mobile phase)(其溶液比例係. 0~10分鐘,B比例為95%〜20% ; 1〇〜20分鐘,B比例為 20〇/〇〜10%; 20〜35分鐘,B比例為1〇〇/。〜1〇%; 35〜4〇分鐘,
c S 12 B比例為·〜95%) ’在每分鐘i ml之速度下沖提,同 時以紫外-可見光全波長偵測器分析。 將25分鐘i 30分鐘之沖提液收集濃縮柯得淡黃 色粉末狀之固體產物,此即4-羥基-2,3-二甲氧基_6_甲美 -5 (3,7,11-三甲基-2,6,10-十二碳三婦)_2_環己稀嗣。經 刀析,其分子式為C24H38〇4,分子量390,炼點(m p ) 1 為48°C〜52°C。核磁共振(NMR)分析值則如下所示: b-NMRCCDCWWppm) : 1.5 卜 1.67、1.7卜 1.75、1 94、 2.03、2.07、2.22、2.25、3.68、4.05、5.07 與 5.14。 13C-NMR(CDC13) 5 (ppm) : 12.31、16.卜 16.12、17.67、 25.67、26.44、26.74、27.00、39.7卜 39.8卜 4.027、43.34、 59.22、60.59、120.97、123.84、124.30、131.32、135 35、 135.92、138.05、160.45 與 197.12。 經將4-羥基-2,3-二甲氧基-6-甲基-5 (3,7,11-三甲基 -2,6,10-十一碳二烯)-2-環己烯酮與化學式資料庫比對 後,並未發現與前述相同之化合物結構,因此,此化合物 係一新穎且前所未見之化合物。 實施例2 : 體外抗乳癌腫瘤細胞之活性測試 為進一步測試實施例1中所發現化合物對腫瘤細胞 之抑制效果’本實施例將根據美國國家癌症研究所 (National Cancer Institute, NCI)抗腫瘤藥物筛檢模式, 13 1330528 首先取實施例1中所分離之4-羥基-2,3-二曱氧基·6-甲基 -5 (3,7,11-三曱基·2,6,10-十二碳三烯)-2-環己烯_化合 物,加入MCF-7與MDA-MB-231人類腫瘤細胞培養液 中’進行腫瘤細胞存活性之測試。細胞存活性之測試可採 習知之ΜΤΤ分析法進行分析’而MCF-7與MDA-MB-231 皆係人類之乳癌腫瘤細胞系。 ΜΤΤ分析法是一種常見用於分析細胞增生(eeU proliferation)、存活率(percent of viable cells)以及細 胞毒性(cytotoxicity)的分析方法。其中,]^1'1'(3-[4,5-dimethylthiazol-2-yl]2,5-diphenyltetrazolium bromide )為一 黃色染劑,它可被活細胞吸收並被粒腺體中的破珀酸四唑 還原酶(succinate tetrazolium reductase )還原成不溶水性 且呈藍紫色的formazan,因此藉由formazan形成與否, 即可判斷並計算細胞之存活率。 首先將人類乳癌細胞MCF-7與MDA-MB-231分別 於含有胎牛血清之培養液中培養24小時。將增生後之細 胞以PBS清洗一次,並以1倍之胰蛋白酶-EDTA處理細 胞,隨後於1,200 rpm下離心5分鐘,將細胞沈澱並丟棄 上清液。之後加入10 ml的新培養液,輕微搖晃使細胞再 次懸浮,再將細胞分置於96孔微量盤内。測試時,分別 於每一孔内加入 30、10、3、1、0.3、0.1 與 〇.〇3 gg/ml 牛樟芝乙醇萃取物(對照組,未經純化分離之總萃取物) 以及4-羥基-2,3-二甲氧基-6-甲基-5( 3,7,11-三甲基-2,6,10- 1330528 十二碳二烯)-2-環己烯酮(試驗組),於37。〇、5% c〇2 下培養48小時。其後’於避光的環境下於每一孔内加入 2.5 mg/ml的MTT’反應4小時後再於每一孔内加入1〇〇 μ1 的lysis buffer終止反應。最後以酵素免疫分析儀在57〇胍 吸光波長下測定其吸光值,藉以計算細胞的存活率,並推 算出其生長半抑制率所需濃度(即IC:5〇值),其結果如 表一所示。
表一:體外對乳癌腫瘤細胞存活率之測試結果 測試樣品 對照組(加入牛樟芝萃取物) Π.132 25.812 0.852 1.031 MCF-7 MDA-MB-231 試驗組(加入式2) MCF-7 MDA-MB-231 由表一中可知,藉由4-羥基-2,3-二甲氧基-6_甲基_5
(3,7,11-二甲基·2,6,10-十二碳三稀)-2-環己歸鋼的作 用,其對於MCF-7人類乳癌腫瘤細胞之1(:5〇值為〇 852 pg/ml’對於MDA-MB-231人類乳癌腫瘤細胞之扣值則 為1.031 pg/m卜相較於牛樟芝萃取混合物所測得之κ 值係低的多’因此可證實牛樟芝萃取物中之4•和武2^ 二曱氧基-6-甲基-5 ( 3,7,11-三曱基-2,6,10-Ί — _ 〜嘴二烯)-2- 環己烯_確實能夠利用於乳癌腫瘤細胞生長之抑制 15 1330528 實施例3 : 體外對乳癌腫瘤細胞輔助治療之活性測試 - 本測試同樣係根據美國國家癌症研究所的體外篩檢 模式進行測試。首先,取人類乳癌細胞MCF-7與 MDA-MB-231,分別於含有胎牛血清之培養液中培養24 小時後,將增生後之細胞以PBS清洗一次,並以1倍之 胰蛋白酶-EDTA處理細胞,隨後於i,2〇〇rpm下離心5分 _ 鐘,將細胞沈殿並丢棄上清液。之後加入1〇 ml的新培養 液,輕微搖晃使細胞再次懸浮。測試前,先加入〇.〇〇17 pg/ml紫杉醇(Taxol)處理細胞72小時,再將細胞分置 於96孔微量盤内,之後分別於每孔内加入0μ§/ιη1 (對照 ' 組),30、10、3、1、0.3、0.1 與 〇.〇3 pg/ml 實施例 1 中 • 所分離之4-羥基-2,3-二曱氧基-6_曱基-5 (3,7,11-三甲基 -2,6,10-十二碳三烯)-2-環己烯酮(試驗組),於37¾、 5% C〇2下培養48小時。其後,於避光的環境下於每一 • 孔内加入2.5mg/ml的MTT’反應4小時後於每一孔内加 入100 μΐ的lysis buffer終止反應。最後以酵素免疫分析 儀在570 nm吸光波長下測定其吸光值,藉以計算細胞的 存活率,並推算出其生長半抑制所需濃度(即IC5〇值), 其結果如表二所示。 表二:體外對乳癌腫瘤細胞經紫杉醇輔助治療後抑制之測 試結果
(S 16 ^30528 __ 測試樣品 結果 對照組 細胞存活率(%) MCF-7 (0.0017 pg/ml Taxol) 65 ±1 MDA-MB-231 (0.0017 pg/ml Taxol) 76±3 試驗組 Κ5〇 (pg/ml) MCT-7 (〇·〇〇ΐ7 pg/mi Taxol+式 2) 0.009 一 MDA-MB-231 (0.0017 pg/ml Taxol+式 2) 0.011 由表一中可知,透過紫杉醇之協同作用,4_經基-2,3_ 二曱氧基-6-曱基-5(3,7,11-三甲基-2,6,1〇-十二碳三烯)_2_ 環己烯酮對於MCF-7人類乳癌腫瘤細胞之IC5〇值降為 0.009 μ_1,對於MDA_MB_231人類乳癌腫瘤細胞之A。 值亦降為約0.011 pg/m卜因此可證實牛樟芝萃取物中之 4山·經基·2’3-二曱氧基-6-曱基_5 ( W !_三ψ基_2,6,1〇_十二 碳三烯)_2-環己稀闕確實能夠利用於乳癌腫瘤細胞生長之 抑制,且在紫杉醇之協同作用下,有更佳之抑制效果。 實施例4 : 體外抗肝癌腫瘤細胞之活性測試 本測試亦係根據美國國家癌症研究所抗腫瘤藥物篩 檢模式進行’將實施例1中所分離之4·經基_2,3-二曱氧美 =基4⑴,"·三甲基々,他十二碳三稀)·2_環己^ 口物,加入Hep 3Β與Hep G2人類肝癌腫瘤細胞培養 液中進仃培養’藉以進行腫瘤細胞存活性之測試。 17 1330528 首先將人類肝癌細胞Hep 3B與Hep G2分別於含有 胎牛血清之培養液中培養24小時。將增生後之細胞以 PBS清洗一次,並以1倍之胰蛋白酶_EDTA處理細胞, 隨後於l,200rpm下離心5分鐘,將細胞沈澱並丟棄上清 液。之後加入10 ml的新培養液,輕微搖晃使細胞再次懸 浮,再將細胞分置於96孔微量盤内。測試時,分別於每 一孔内加入 30、10、3、1、〇.3、〇.1 與 〇.〇3 pg/mi 之牛樟 k乙醇萃取物(對照組’未經純化分離之總萃取物)以及 30、10、3、卜 0.3、0.1 與 〇.〇3 pg/mi 之 4-經基-2,3-二甲 氧基-6-甲基·5 (3,7,11-三甲基_2,6,1〇_十二碳三烯)·2_環己 埽酮(試驗組)’於37°C、5% C02下培養48小時。其 後,於避光的環境下於每一孔内加入2.5 mg/ml的MTT, 反應4小時後再於母一孔内加入1 〇〇 μΐ的lysis buffer終 止反應。最後以酵素免疫分析儀在570 nm吸光波長下測 定其吸光值,藉以計算細胞的存活率,並推算出其IC50 值’其結果如表三所示。 表三:體外對肝癌腫瘤細胞抑制之測試結果 測試樣品 IC50 ( Mg/ml) 對照組(加入牛樟芝萃取物} Hep 3B 5.121 Hep G2 18.631 試驗組(加入式2) Hep 3B 0.005 Hep G2 1.679 18 1330528 由表广中可知,藉由4-經基-2,3-二甲氧基-6-甲基·5 (’,1 -甲土 2,6,ΐ〇·十二碳三豨)2·環己歸綱的作用, 其對於Hep 3Β人類肝癌腫瘤細胞之IC50值降為_ μ#,對於Hep G2人類肝癌腫瘤細胞之 ⑽9—1,㈣你牛料萃祕合物所導 係低的多,因此可證實牛樟芝萃取物中之4_絲_2,3_二甲 氧基_6_甲基-5 ( 3’7,11_三曱基·2,6,1〇十二碳三稀)’_2環己 烯酮確實能夠利用於肝癌腫瘤細胞生長之抑制。 實施例5 : 體外對肝癌腫瘤細胞辅助治療之活性測試 本測试同樣係根據美國國家癌症研究所的體外篩檢 模式進行測試。首先,取人類肝癌細胞Hep 3B與Hep G2 ’分別於含有胎牛血清之培養液中培養24小時後,將 增生後之細胞以PBS清洗一次,並以1倍之胰蛋白酶 -EDTA處理細胞,隨後於1,200 rpm下離心5分鐘,將細 胞沈澱並丢棄上清液。之後加入10 ml的新培養液,輕微 搖晃使細胞再次懸浮。測試前,先於Hep 3B細胞株試驗 加入0.0043 gg/ml Lovastatin,而於Hep G2細胞株試驗加 入0.0017 pg/ml紫杉醇(Taxol),處理細胞72小時,再 將細胞分置於96孔微量盤内,之後分別於每孔内加入〇 pg/ml (對照組),30、10、3、1、0.3、0.1 與 〇.〇3 gg/mi 實施例1中所分離之4-羥基-2,3-二甲氧基-6-甲基·5 19 1330528 (3,7,11·三甲基_2,6,l〇_十二碳三烯)_2_環己烯酮(試驗 組),於37°C、5% C02下培養48小時。其後,於避 光的環境下於每一孔内加入2.5 mg/ml的MTT,反應4 小時後於母一孔内加入1〇〇 μΐ的lySis buffer終止反應。 最後以酵素免疫分析儀在570 nm吸光波長下測定其吸 光值’藉以計算細胞的存活率,並推算出其IC5〇值,其 結果如表四所示。 表四:體外對肝癌腫瘤細胞經紫杉醇辅助治療後抑制之測 試結果 測試樣品 結果 對照組 細胞存活率(%) Hep 3Β (0.0043 pg/ml Lovastatin) 61±3 Hep G2 (0.0017 μ8/ηι1 Taxol) 81+2 試驗組 IC50 ( pg/ml) Hep 3B (0.0043 pg/mi L〇vastatin+式 2) 0.002 Hep G2 (0.0017 pg/ml Taxol + 式 2) 0.008 由表四中可知,透過Lovastatin及紫杉醇之協同作 用,4·經基-2,3-二曱氧基-6-曱基-5 (3,7,11-三甲基-2,6,10-十二碳三烯)-2-環己烯酮對於Hep 3B人類肝癌腫瘤細胞 之IQo值降為0.002 pg/ml,對於Hep G2人類肝癌腫瘤細 胞之IC50值亦降為約0.008 pg/m卜因此可證實牛樟芝萃 取物中之4-經基-2,3-二曱氧基-6-曱基-5 ( 3,7,11-三曱基 -2,6,10-十二碳三烯)·2_環己烯酮確實能夠利用於肝癌腫瘤 20 細胞生長之抑制,且在紫杉醇之協同作用下,有更佳之抑 制效果。 實施例6 : 體外抗攝護腺癌腫瘤細胞之活性測試 本測試亦係根據美國國家癌症研究所抗腫瘤藥物篩 檢模式進行’將實施例1中所分離之4-經基-2,3-二曱氧基 -6-曱基·5 (3,7,ll-三曱基-2,6,10-十二碳三烯)_2_環己烯酮 化合物,加入LNCaP與DU-145人類攝護腺癌腫瘤細胞 培養液中進行培養’藉以進行腫瘤細胞存活性之測試。 首先將人類攝護腺癌細胞LNCaP與DU-145分別於 含有胎牛血清之培養液中培養24小時。將增生後之細胞 以PBS清洗一次,並以1倍之胰蛋白酶-EDTA處理細胞, 隨後於1,200 rpm下離心5分鐘,將細胞沈澱並丟棄上清 液。之後加入10 ml的新培養液,輕微搖晃使細胞再次懸 浮,再將細胞分置於96孔微量盤内。測試時,分別於每 一孔内加入30、10、3、1與0.3 pg/ml牛樟芝乙醇萃取物 (對照組,未經純化分離之總萃取物)以及30、10、3、1 與0.3 pg/ml由實施例1所分離之4-羥基-2,3-二曱氧基-6-曱基-5( 3,7,11-三曱基-2,6,10-十二碳三稀)-2-環己稀飼(試 驗組),於37t、5% C02下培養48小時。其後,於 避光的環境下於每一孔内加入2.5 mg/ml的MTT,反應4 小時後再於每一孔内加入1〇〇 μΐ的lysis buffer終止反 21 1330528 應。最後以酵素免疫分析儀在570 nm吸光波長下測定其 吸光值’藉以計算細胞的存活率,並推算出其IC50值, 其結果如表五所示。 表五:體外對攝護腺癌腫瘤細胞抑制之測試結果 測試樣品 IC5〇 (pg/ml) 對照組(加入牛樟芝萃取物) LNCaP 11.491 DU-145 41.392 試驗組(加入式2) LNCaP 2.378 DU-145 1.812 由表五中可知,藉由4-羥基-2,3-二曱氧基·6-甲基_5 (3,7,11-三甲基_2,6,1〇-十二碳三稀卜2-環己烯_的作用, 其對於LNCaP人類攝護腺癌腫瘤細胞之『Μ值降為 • μδ/ιη卜對於DU_145人嶋護腺癌腫瘤細胞之ic5〇值則 降為1.812 pg/ml,相較於牛樟芝萃取混合物所測得之忙 值係低❹,目此可證實牛財萃取财之㈣ s〇 —曱氧基-6-甲基-5 ( 3,7,11-三甲基-2,6,1()_十二碳’ 環己_確實能夠利用於»護腺癌腫瘤細胞生長^抑^2- 實施例7 : 體外對攝護腺癌膜瘤細胞輔助治療之活性測試
22 1330528 本測試同樣係根據美國國家癌症研究所的體外篩檢 模式進行測試。首先,取人類攝護腺癌細胞LNCaP與 DU-145,分別於含有胎牛金清之培養液中培養24小時 後,將增生後之細胞以PBS清洗一次,並以1倍之胰蛋 白酶-EDTA處理細胞,隨後於1,200 rpm下離心5分鐘, 將細胞沈澱並丟棄上清液。之後加入10 ml的新培養液, 輕微搖晃使細胞再次懸浮。測試前,先於LNCaP細胞株 試驗加入0.0017 pg/ml紫杉醇,而於DU-145胞株試驗加 入0.0043 pg/ml紫杉醇分別處理細胞72小時,再將細胞 分置於96孔微量盤内,之後分別於每孔内加入〇 pg/ml (對照組)’ 30、10、3、1、0.3、0·1 與 0.03 pg/ml 於實施 例1中所分離之4-經基-2,3-二曱氧基-6-曱基-5 (3,7,11-三甲基-2,6,10-十二碳三烯)-2-環己稀嗣(試驗組),於 37°C、5% C〇2下培養48小時。其後,於避光的環境下 於每一孔内加入2.5 mg/ml的MTT,反應4小時後於每一 孔内加入100 μΐ的lysis buffer終止反應。最後以酵素免 疫分析儀在570 nm吸光波長下測定其吸光值,藉以計算 細胞的存活率’並推鼻出其IC5Q值’其結果如表六所示。 表六:體外對攝護腺癌腫瘤細胞經紫杉醇辅助治療後抑 制之測試結果 _測試樣品_ 結果 對照組 細胞存活率(〇/〇) LNCaP (0.0017 μβ/ιηΐ Taxol) 56±3 DU-145 (0.0043 pg/ml Taxol) 70±2 23 1330528 試驗組 LNCaP (〇.〇〇i7pg/mi Taxol+式 2) 0.961 DU-145 (〇.〇〇43pg/ml Taxol+式 2)___0.515
由表六中可知,透過紫杉醇之協同作用,‘經基_2卩_ 二曱氧基-6-曱基-5 ( 3,7,11-三曱基-2,6,l〇-十二碳三烯)·2· 環己烯酮對於LNCaP人類攝護腺癌腫瘤細胞之IC5g值降 為0.961 pg/ml,對於DU_145人類攝護腺癌腫瘤細胞之 忙兄值亦降為約0.515 pg/m卜相較於牛樟芝萃取混合物 所測得之IC5〇值係低的多,因此可證實牛樟芝萃取物中 之4-經基-2,3·二曱氧基-6-甲基-5 (3,7,11-三甲基_2,6,1〇_ 十一叙二稀)-2-環己嫦酮破實能夠利用於攝護腺癌腫瘤細 胞生長之抑制,且在紫杉醇之協同作用下,有更佳之抑制 效果。 實施例8 : 體外抗氧化活性之試驗 一般抗氧化活性之測試,係利用人類低密度脂蛋白 (human low density lipoprotein,LDL),加入銅離子(Cu2+) 與待測樣本進行氧化反應,檢測LDL上二烯之反應結果後, 以維生素E之水溶性類似物Trolox作為對照(;ΤΓ〇1〇χ濃度為 2μΜ時,其效力值訂為標準值丨.0),計算出待測樣本之抗 氧化活性。 24 1330528 首先準備二次純水(控制組),並配製5 ^磷酸鈉緩衝 溶液(sodium phosphate buffer’ SPB )、1 μΜ 與 2 μΜ 的 Trolox (對照組)及40 pg/ml由實施例1中所分離之4_羥基_2,3_二曱 氧基-6-甲基-5 (3,7,11-三曱基_2,6,10-十二碳三烯)_2_環己烯 酮(試驗組)。利用酵素法測得低密度膽固醇濃度(LDL_C) 後’利用5 mM SPB將LDL稀釋至0.10〜0.25 mg/ml間。取 96孔的石英微量盤’於其中先加入100 μ1之LDL,再分別加 入前述預定濃度的Trolox及由實施例1中所分離之化合物, 之後再分別加入CuS〇4溶液以啟動氧化反應(每一 250 μΐ孔 中的銅(II)濃度為5.0 μΜ),最後將該微量盤置於酵素免疫 微量盤分析儀(ELISAreader)中進行檢測。酵素免疫微量盤 分析儀檢測波長設為232 nm,溫度設為37°C,债測時間為 12小時’採樣間隔時間為15分鐘,其結果如表七所示。 表七:體外抗氧化活性之測試結果 測試樣品 Tlag(分) △Tlag(分) 效力值 氏0(控制紙Tlago) 185 1 μΜ Trolox (對照组) 266 81 0.48 2 μΜ Trolox 344 159 1.00 40 ng/mL 式 2 439 208 1.30 §主1.丁13^('$7)係指在吸收光波長為23411111下’延滞期(1咕口11386) 與連鎖期(propagation phase)的交差點;ATlag(分)係指各測試 樣品Tlag時間與Tlag〇時間的差值。 註2 :效力值Χ)·5時,表示其具抗氧化作用。 25 1330528 由表七中可知,4·經基_2,3-二甲氧基_6_甲基_5 (3,7,u_ 二甲基-2,6,10-十一峡二稀)-2-環己缔_具有i 之效力值, 其比具抗氧化能力之標準值0.5高出甚多,亦即,其具有相 當之抗氧化能力,因此可用作保健食品、飲食品、醫藥品、 化妝品當中之成分,藉由其抗氧化能力達到預防心血管疾病 或避免細胞突變等效用,使對於施用之人體健康產生莫大的 助益。 【圖式簡單說明】 無 【主要元件符號說明】 無 26
Claims (1)
- ” v ; k 十、申請專利範圍: 、 1、一種化合物,包括下列結構式:其中,X係氧(Q)或硫(S),γ係、氧或硫;心 係氫基(Η)、曱基(CH3)或(CH2)m_CH3,& 係1 氫基、曱基或(CH2)m-CH3,&係氫基、甲基咬 (CH2)m-CH3,m=l〜12 ; n=l〜12。 2、 一種將如申請專利範圍第丨項所述化合物利用於掣 備抑制乳癌腫瘤細胞生長之藥物的應用。 3、 如申請專利範圍第2項所述之應用,其中該乳癌腫 瘤細胞係MCF-7或MDA-MB-231細胞系。 4、 一種將如申請專利範圍第1項所述化合物利用於製 備抑制肝癌腫瘤細胞生長之藥物的應用。 5、 如申請專利範圍第4項所述之應用,其中該肝癌腫 瘤細胞係Hep 3B或Hep G2細胞系。 6、 一種將如申請專利範圍第1項所述化合物利用於製 備抑制攝護腺癌腫瘤細胞生長之藥物的應用。 7、 如申請專利範圍第6項所述之應用,其中該攝護腺 癌腫瘤細胞係LNCaP或DU145細胞系。 27 1330528 .. 8、一種將如申請專利範圍第1項所述之化合物利用於 *. · ·. 製備具抗氧化活性之藥物的應用。 .. 9、一種利用於抑制腫瘤細胞生長之醫藥組成物,包括 % 一有效劑量如申請專利範圍第1項所述之化合物 以及一藥學上可接受之載體,其中該腫瘤細胞係選 自乳癌、肝癌或攝護腺癌之腫瘤細胞。28
Priority Applications (25)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW096100680A TW200829234A (en) | 2007-01-08 | 2007-01-08 | Antrodia camphorata isophorone extract |
US11/747,407 US7342137B1 (en) | 2007-01-08 | 2007-05-11 | Cyclohexenone compounds from Antrodia camphorata and application thereof |
JP2007126866A JP5085186B2 (ja) | 2007-01-08 | 2007-05-11 | ベニクスノキタケから単離された新規化合物 |
DE102007022161A DE102007022161A1 (de) | 2007-01-08 | 2007-05-11 | neue Cyclohexenonverbindungen aus Antrodia camphorata und deren Anwendung |
GB0709171A GB2445430A (en) | 2007-01-08 | 2007-05-14 | 4-hydroxy-2,3-disubstituted-cyclohex-2-en-1-on-5-yl isoprenoids, extractable from Antrodia camphorata, as anti-tumour & cardiovascular agents, & antioxidant |
KR1020070056701A KR101011616B1 (ko) | 2007-01-08 | 2007-06-11 | 안트로디아 캄포라타로부터 얻은 신규 시클로헥세논 화합물및 그의 적용 |
FR0704175A FR2911133A1 (fr) | 2007-01-08 | 2007-06-12 | Nouveaux composes de cyclohexenone provenant d'antrodia camphorata et application de ceux-ci |
ZA200800150A ZA200800150B (en) | 2007-01-08 | 2008-01-01 | Novel cyclohexenone compounds from antrodia camphorata and application thereof |
NZ564913A NZ564913A (en) | 2007-01-08 | 2008-01-04 | Novel cyclohexenone compounds from antrodia camphorata and application thereof |
NO20080078A NO20080078L (no) | 2007-01-08 | 2008-01-04 | Nye syklohexononforbindelser fra antrodia comphorata og anvendelser derav |
MYPI20080021A MY144944A (en) | 2007-01-08 | 2008-01-07 | Novel cyclohexenone compounds from antrodia camphorata and application thereof |
SG200800098-6A SG144815A1 (en) | 2007-01-08 | 2008-01-07 | Novel cyclohexenone compounds from antrodia camphorata and application thereof |
AU2008200063A AU2008200063C1 (en) | 2007-01-08 | 2008-01-07 | Novel cyclohexenone compounds from antrodia camphorata and application thereof |
CA2618271A CA2618271C (en) | 2007-01-08 | 2008-01-07 | Novel cyclohexenone compounds from antrodia camphorata and application thereof |
BRPI0800401-3A BRPI0800401A (pt) | 2007-01-08 | 2008-01-08 | novos compostos da ciclohexenona a partir da antrodia camphorata e suas aplicações |
ARP080100073A AR064788A1 (es) | 2007-01-08 | 2008-01-08 | Compuestos de ciclohexenona de la antrodia comphorata y usos de los mismos |
EP08250090A EP1942093B1 (en) | 2007-01-08 | 2008-01-09 | Novel cyclohexenone compounds from antrodia camphorata and application thereof |
SI200830296T SI1942093T1 (sl) | 2007-01-08 | 2008-01-09 | Nove cikloheksenonske spojine iz antrodia camphorata in njihove aplikacije |
ES08250090T ES2365888T3 (es) | 2007-01-08 | 2008-01-09 | Compuestos de ciclohexenona novedosos procedentes de antrodia camphorata y sus aplicaciones. |
PT08250090T PT1942093E (pt) | 2007-01-08 | 2008-01-09 | Novos compostos de cyclohexenone a partir de antrodia camphorata e sua aplicação |
AT08250090T ATE509005T1 (de) | 2007-01-08 | 2008-01-09 | Neuartige cyclohexenon-verbindungen aus antrodia camphorata und anwendungen dafür |
DK08250090.1T DK1942093T5 (da) | 2007-01-08 | 2008-01-09 | Hidtil ukendte cyclohexenon-forbindelser fra antrodia camphorata og anvendelse deraf |
PL08250090T PL1942093T3 (pl) | 2007-01-08 | 2008-01-09 | Nowe związki cykloheksenonowe z Antrodia camphorata oraz ich zastosowanie |
CY20111100713T CY1111722T1 (el) | 2007-01-08 | 2011-07-20 | Νεες ενωσεις κυκλοεξενονης απο antrodia camphorata και εφαρμογες αυτων |
HR20110588T HRP20110588T1 (hr) | 2007-01-08 | 2011-08-04 | Novi cikloheksenonski spojevi iz antrodia camphorata i njihova primjena |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW096100680A TW200829234A (en) | 2007-01-08 | 2007-01-08 | Antrodia camphorata isophorone extract |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200829234A TW200829234A (en) | 2008-07-16 |
TWI330528B true TWI330528B (zh) | 2010-09-21 |
Family
ID=38219309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW096100680A TW200829234A (en) | 2007-01-08 | 2007-01-08 | Antrodia camphorata isophorone extract |
Country Status (25)
Country | Link |
---|---|
US (1) | US7342137B1 (zh) |
EP (1) | EP1942093B1 (zh) |
JP (1) | JP5085186B2 (zh) |
KR (1) | KR101011616B1 (zh) |
AR (1) | AR064788A1 (zh) |
AT (1) | ATE509005T1 (zh) |
AU (1) | AU2008200063C1 (zh) |
BR (1) | BRPI0800401A (zh) |
CA (1) | CA2618271C (zh) |
CY (1) | CY1111722T1 (zh) |
DE (1) | DE102007022161A1 (zh) |
DK (1) | DK1942093T5 (zh) |
ES (1) | ES2365888T3 (zh) |
FR (1) | FR2911133A1 (zh) |
GB (1) | GB2445430A (zh) |
HR (1) | HRP20110588T1 (zh) |
MY (1) | MY144944A (zh) |
NO (1) | NO20080078L (zh) |
NZ (1) | NZ564913A (zh) |
PL (1) | PL1942093T3 (zh) |
PT (1) | PT1942093E (zh) |
SG (1) | SG144815A1 (zh) |
SI (1) | SI1942093T1 (zh) |
TW (1) | TW200829234A (zh) |
ZA (1) | ZA200800150B (zh) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI394572B (zh) * | 2007-06-12 | 2013-05-01 | Golden Biotechnology Corp | Application of Cynanchum aurantii Cyclohexenone Compounds in the Preparation of Drugs for the Treatment of Autoimmune Diseases |
TWI394573B (zh) * | 2007-06-14 | 2013-05-01 | Golden Biotechnology Corp | Application of Cynanchum auranthone Cyclohexenone Compounds in the Preparation of Drugs for Liver Protection |
CN101333156B (zh) * | 2007-06-27 | 2011-07-20 | 国鼎生物科技股份有限公司 | 牛樟芝环己烯酮化合物的制备方法及其应用 |
TWI394575B (zh) * | 2007-07-09 | 2013-05-01 | Golden Biotechnology Corp | Application of Cynanchum auranthone Cyclohexenone Compounds in the Preparation of Drugs for the Suppression of Hepatitis B Virus |
JP5203644B2 (ja) * | 2007-07-13 | 2013-06-05 | 國鼎生物科技股▲ふん▼有限公司 | 自己免疫疾病の治療に用いるベニクスノキタケ由来の化合物 |
JP5106935B2 (ja) * | 2007-07-17 | 2012-12-26 | 國鼎生物科技股▲ふん▼有限公司 | 生理的疲労の緩和に用いるベニクスノキタケのシクロヘキサンケトン化合物 |
CN101357883B (zh) * | 2007-07-30 | 2012-09-26 | 国鼎生物科技股份有限公司 | 治疗自体免疫疾病的牛樟芝环己烯酮化合物及医药组成物 |
CN101362679B (zh) * | 2007-08-08 | 2012-05-30 | 国鼎生物科技股份有限公司 | 用于抑制b型肝炎病毒的牛樟芝环己烯酮化合物 |
CN101376624B (zh) * | 2007-08-29 | 2011-06-01 | 国鼎生物科技股份有限公司 | 用于护肝的牛樟芝环己烯酮化合物 |
CN101417934B (zh) * | 2007-10-24 | 2012-04-18 | 国鼎生物科技股份有限公司 | 分离自牛樟芝萃取物的化合物 |
TW201102075A (en) * | 2009-07-09 | 2011-01-16 | Golden Biotechnology Corp | Cyclohexenone compound of Antrodia cinnomomea that suppresses growth of tumor cell of pancreatic cancer |
TW201102076A (en) * | 2009-07-09 | 2011-01-16 | Golden Biotechnology Corp | Cyclohexenone compound of Antrodia cinnomomea suppressing growth of tumor cell of osteosarcoma |
TW201109023A (en) * | 2009-09-09 | 2011-03-16 | Golden Biotechnology Corp | Cyclohexenone compound of Antrodia cinnomomea that suppresses growth of tumor cell of colorectal cancer |
TWI394566B (zh) * | 2009-09-09 | 2013-05-01 | Golden Biotechnology Corp | Used to inhibit the growth of ovarian cancer tumor cells of the cattle camphor cyclohexene ketone compounds |
TW201109024A (en) * | 2009-09-09 | 2011-03-16 | Golden Biotechnology Corp | Cyclohexenone compound of Antrodia cinnomomea that suppresses growth of tumor cell of bladder cancer |
TWI383790B (zh) * | 2009-09-09 | 2013-02-01 | Golden Biotechnology Corp | Used to inhibit the growth of oral cancer cells of the cattle Antrodylcyclohexenone compounds |
TWI383791B (zh) * | 2009-09-09 | 2013-02-01 | Golden Biotechnology Corp | Used to inhibit the growth of gastric cancer tumor cells of the male antler ketone compounds |
TW201109013A (en) * | 2009-09-09 | 2011-03-16 | Golden Biotechnology Corp | Cyclohexenone chemical compounds of Antrodia cinnamomea for suppressing the growth of the Lymphoma tumor cell |
TW201109014A (en) * | 2009-09-09 | 2011-03-16 | Golden Biotechnology Corp | Cyclohexenone compound of Antrodia cinnomomea that suppresses growth of tumor cell of skin cancer |
ES2574606T3 (es) * | 2009-11-26 | 2016-06-21 | National Taiwan University | Una sustancia activa contra el cáncer de Antrodia camphorata, método de preparación de la misma y uso de la misma |
US8309611B2 (en) * | 2010-09-20 | 2012-11-13 | Golden Biotechnology Corporation | Methods and compositions for treating lung cancer |
TWI452032B (zh) | 2011-01-21 | 2014-09-11 | Golden Biotechnology Corp | 治療腎病之醫藥組成物 |
US20130158113A1 (en) * | 2011-06-10 | 2013-06-20 | Golden Biotechnology Corporation | Methods and compositions for treating brain cancer |
FR2987264A1 (fr) | 2012-02-23 | 2013-08-30 | Golden Biotechnology Corp | Methodes et compositions pour le traitement des metastases cancereuses |
CN104220083B (zh) * | 2012-03-26 | 2018-11-27 | 国鼎生物科技股份有限公司 | 用于治疗动脉硬化性血管疾病的方法和组合物 |
CN104968339B (zh) * | 2012-11-21 | 2019-06-11 | 国鼎生物科技股份有限公司 | 用于治疗神经变性疾病的方法和组合物 |
CN103058846B (zh) * | 2013-01-17 | 2014-07-30 | 福州大学 | 一种源于棘孢曲霉的苯醌衍生物及其应用 |
US20150018296A1 (en) * | 2013-03-15 | 2015-01-15 | Golden Biotechnology Corporation | Therapeutic methods and compositions utilizing cyclohexenone compounds |
TWI583376B (zh) * | 2013-03-20 | 2017-05-21 | Hui-Ling Zeng | Compounds isolated from Antelroxicus and their use |
TW201521752A (zh) * | 2013-12-05 | 2015-06-16 | Univ Nat Taiwan Normal | 牛樟芝於抗肥胖的應用及其方法 |
EP3984537B1 (en) * | 2013-12-20 | 2024-03-20 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of type 2 mek and erk inhibitors |
CN104522794B (zh) * | 2014-12-04 | 2017-01-11 | 深圳市仁泰生物科技有限公司 | 樟芝解毒饮料及其制备方法 |
PL3240772T3 (pl) * | 2014-12-30 | 2021-06-28 | ONENESS BIOTECH CO., Ltd | Związki z antrodia camphorata, sposoby ich otrzymywania i ich zastosowanie |
TWI637746B (zh) * | 2016-01-20 | 2018-10-11 | 台灣利得生物科技股份有限公司 | 固態培養牛樟芝菌絲體及子實體萃取物之組合物作為腫瘤抑制劑之應用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3064012A (en) * | 1960-07-20 | 1962-11-13 | Merck & Co Inc | Derivatives of coenzyme q10 |
EP0205576A1 (en) * | 1984-12-17 | 1986-12-30 | Harbor Branch Oceanographic Institution, Inc. | Antiviral and antitumor cyclohexadienone compositions |
TWI226370B (en) * | 2000-02-17 | 2005-01-11 | Food Industry Res & Dev Inst | Isolate of Antrodia camphorata, process for producing a culture of the same and product obtained thereby |
US6767543B2 (en) * | 2000-02-17 | 2004-07-27 | Council Of Agriculture, Executive Yuan | Process for producing a culture of Antrodia camphorata and product obtained thereby |
JP5403844B2 (ja) * | 2004-03-02 | 2014-01-29 | 善笙生物科技股▲分▼有限公司 | AntrodiaCamphorataの菌糸体から得た新規な混合物及び化合物、並びにその使用 |
US7109232B2 (en) * | 2004-03-08 | 2006-09-19 | Simpson Biotech Co., Ltd. | Compounds from Antrodia camphorata having anti-inflammatory and anti-tumor activity |
TW200638867A (en) * | 2005-05-06 | 2006-11-16 | Golden Biotechnology Corp | Incubation and application methods for the culture of antrodia camphorata |
US20070116787A1 (en) * | 2005-11-21 | 2007-05-24 | Chih-Jung Yao | Cancer treatment |
-
2007
- 2007-01-08 TW TW096100680A patent/TW200829234A/zh unknown
- 2007-05-11 DE DE102007022161A patent/DE102007022161A1/de not_active Withdrawn
- 2007-05-11 US US11/747,407 patent/US7342137B1/en active Active
- 2007-05-11 JP JP2007126866A patent/JP5085186B2/ja active Active
- 2007-05-14 GB GB0709171A patent/GB2445430A/en not_active Withdrawn
- 2007-06-11 KR KR1020070056701A patent/KR101011616B1/ko active IP Right Grant
- 2007-06-12 FR FR0704175A patent/FR2911133A1/fr active Pending
-
2008
- 2008-01-01 ZA ZA200800150A patent/ZA200800150B/en unknown
- 2008-01-04 NZ NZ564913A patent/NZ564913A/en not_active IP Right Cessation
- 2008-01-04 NO NO20080078A patent/NO20080078L/no not_active Application Discontinuation
- 2008-01-07 SG SG200800098-6A patent/SG144815A1/en unknown
- 2008-01-07 MY MYPI20080021A patent/MY144944A/en unknown
- 2008-01-07 AU AU2008200063A patent/AU2008200063C1/en active Active
- 2008-01-07 CA CA2618271A patent/CA2618271C/en active Active
- 2008-01-08 AR ARP080100073A patent/AR064788A1/es not_active Application Discontinuation
- 2008-01-08 BR BRPI0800401-3A patent/BRPI0800401A/pt not_active Application Discontinuation
- 2008-01-09 PT PT08250090T patent/PT1942093E/pt unknown
- 2008-01-09 SI SI200830296T patent/SI1942093T1/sl unknown
- 2008-01-09 ES ES08250090T patent/ES2365888T3/es active Active
- 2008-01-09 DK DK08250090.1T patent/DK1942093T5/da active
- 2008-01-09 PL PL08250090T patent/PL1942093T3/pl unknown
- 2008-01-09 EP EP08250090A patent/EP1942093B1/en active Active
- 2008-01-09 AT AT08250090T patent/ATE509005T1/de active
-
2011
- 2011-07-20 CY CY20111100713T patent/CY1111722T1/el unknown
- 2011-08-04 HR HR20110588T patent/HRP20110588T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
CY1111722T1 (el) | 2015-10-07 |
ATE509005T1 (de) | 2011-05-15 |
GB0709171D0 (en) | 2007-06-20 |
US7342137B1 (en) | 2008-03-11 |
KR20080065218A (ko) | 2008-07-11 |
SG144815A1 (en) | 2008-08-28 |
AU2008200063A1 (en) | 2008-07-24 |
DK1942093T5 (da) | 2012-04-02 |
ZA200800150B (en) | 2009-08-26 |
AU2008200063C1 (en) | 2011-05-19 |
TW200829234A (en) | 2008-07-16 |
EP1942093B1 (en) | 2011-05-11 |
AU2008200063B2 (en) | 2010-01-07 |
AR064788A1 (es) | 2009-04-22 |
MY144944A (en) | 2011-11-30 |
CA2618271C (en) | 2010-08-31 |
HRP20110588T1 (hr) | 2011-11-30 |
ES2365888T3 (es) | 2011-10-13 |
PT1942093E (pt) | 2011-08-23 |
KR101011616B1 (ko) | 2011-01-27 |
JP5085186B2 (ja) | 2012-11-28 |
CA2618271A1 (en) | 2008-07-08 |
DK1942093T3 (da) | 2011-08-29 |
SI1942093T1 (sl) | 2012-01-31 |
PL1942093T3 (pl) | 2011-10-31 |
DE102007022161A1 (de) | 2008-07-10 |
FR2911133A1 (fr) | 2008-07-11 |
GB2445430A (en) | 2008-07-09 |
JP2008169194A (ja) | 2008-07-24 |
EP1942093A1 (en) | 2008-07-09 |
NZ564913A (en) | 2009-05-31 |
BRPI0800401A (pt) | 2008-08-26 |
NO20080078L (no) | 2008-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI330528B (zh) | ||
TWI335314B (zh) | ||
TWI394575B (zh) | Application of Cynanchum auranthone Cyclohexenone Compounds in the Preparation of Drugs for the Suppression of Hepatitis B Virus | |
CN101225066B (zh) | 牛樟芝的环己烯酮萃取物 | |
CN101417934B (zh) | 分离自牛樟芝萃取物的化合物 | |
WO2008086743A1 (fr) | Application d'un extrait d'antrodia cinnamomea pour l'inhibition de la croissance de cellules tumorales | |
TWI394566B (zh) | Used to inhibit the growth of ovarian cancer tumor cells of the cattle camphor cyclohexene ketone compounds | |
TWI302834B (zh) | ||
TW201102075A (en) | Cyclohexenone compound of Antrodia cinnomomea that suppresses growth of tumor cell of pancreatic cancer | |
TWI383791B (zh) | Used to inhibit the growth of gastric cancer tumor cells of the male antler ketone compounds | |
CN101343247B (zh) | 牛樟芝的环己烯酮萃取物 | |
TWI361687B (zh) | ||
TWI379678B (zh) | ||
CN104177240A (zh) | 分离自牛樟芝的化合物、萃取物及其用途 | |
TW201102076A (en) | Cyclohexenone compound of Antrodia cinnomomea suppressing growth of tumor cell of osteosarcoma | |
TWI583376B (zh) | Compounds isolated from Antelroxicus and their use | |
TWI379679B (zh) | ||
TWI383790B (zh) | Used to inhibit the growth of oral cancer cells of the cattle Antrodylcyclohexenone compounds | |
TWI379685B (zh) | ||
CN102000046B (zh) | 牛樟芝环己烯酮化合物在制备用于抑制胰脏癌肿瘤细胞生长的药物中的应用 | |
CN101362679A (zh) | 用于抑制b型肝炎病毒的牛樟芝环己烯酮化合物 | |
CN102232946B (zh) | 牛樟芝环己烯酮化合物在制备用于抑制胃癌肿瘤细胞生长的药物的用途 | |
CN104211627A (zh) | 牛樟芝化合物、萃取物及其用途 | |
TW201319052A (zh) | 一種聚乙炔化合物、含其之萃取物及其運用 | |
CN102232945A (zh) | 用于抑制膀胱癌肿瘤细胞生长的牛樟芝环己烯酮化合物 |